Abstract-Monocyte chemoattractant protein-1 (MCP-1)/monocyte chemotactic and activating factor (MCAF) has been suggested to promote atherogenesis. The effects of in vivo neutralization of MCP-1 in a rat model were examined in an effort to clarify the role of MCP-1 in the development of neointimal hyperplasia. Competitive polymerase chain reaction analysis revealed maximum MCP-1 mRNA expression at 4 hours after carotid arterial injury. Increased immunoreactivities of MCP-1 were also detected at 2 and 8 hours after injury. Either anti-MCP-1 antibody or nonimmunized goat IgG (10 mg/kg) was then administered every 12 hours to rats that had undergone carotid arterial injury. Treatment with 3 consecutive doses of anti-MCP-1 antibody within 24 hours (experiment 1) and every 12 hours for 5 days (experiment 2) significantly inhibited neointimal hyperplasia at day 14, resulting in a 27.8% reduction of the mean intima/media ratio (PϽ0.05) in experiment 1 and a 43.6% reduction (PϽ0.01) in experiment 2. This effect was still apparent at day 56 (55.6% inhibition; PϽ0.05). The number of vascular smooth muscle cells in the neointima at day 4 was significantly reduced by anti-MCP-1 treatment, demonstrating the important role of MCP-1 in early neointimal lesion formation. However, recombinant MCP-1 did not stimulate chemotaxis of vascular smooth muscle cells in an in vitro migration assay. These results suggest that MCP-1 promotes neointimal hyperplasia in early neointimal lesion formation and that neutralization of MCP-1 before, and immediately after, arterial injury may be effective in preventing restenosis after angioplasty. Further studies are needed to clarify the mechanism underlying the promotion of neointimal hyperplasia by MCP-1. (Circ Res. 1999;84:306-314.)
L ate restenosis after balloon angioplasty remains the most limiting factor with regard to the long-term effectiveness of the procedure, and it is partially attributed to neointimal hyperplasia. 1, 2 Despite some success of various treatments [3] [4] [5] in reducing neointimal hyperplasia in animal models, no sufficiently effective therapy has been confirmed in clinical trials. In the development of neointima, several cell types, such as monocytes/macrophages, vascular smooth muscle cells (VSMCs), and T lymphocytes, play diverse roles. Growth factors and cytokines mediate the interactions among these cells. 6, 7 One of these soluble factors, monocyte chemoattractant protein-1 (MCP-1)/monocyte chemotactic and activating factor (MCAF), has been reported to be expressed early in the injured arterial wall. 8 MCP-1 is a potent chemotactic factor of monocytes 9, 10 and is produced by activated endothelial cells 11 and VSMCs. 12 It has also been detected in human atheromatous plaques using immunohistochemical staining and in situ hybridization. 13 Monocytes/macrophages recruited into injured arterial walls become foam cells, the focal accumulation of which may play a pivotal role in atherogenesis, 6, 14 including in restenosis. A recent clinical study found that activation of blood monocytes before angioplasty promotes late lumen loss after percutaneous transluminal coronary angioplasty. 15 Thus, MCP-1 may have a promoting role in neointimal hyperplasia. However, 2 opposite effects have been reported with respect to the mitogenic activity of MCP-1 on cultured VSMC proliferation. 16, 17 This suggests diverse effects of MCP-1 during the development of neointimal hyperplasia.
The purpose of this study was to clarify which action, facilitating or inhibitory, of MCP-1 is more prominent in vivo. First, the time course of the expression of MCP-1 in injured artery was studied by competitive reverse transcriptase-polymerase chain reaction (PCR) and tissue ELISA. On the basis of these results, the effects of anti-MCP-1 treatment in a rat carotid arterial injury model were investigated.
Materials and Methods

Anti-MCP-1 Antibody (Ab) and Other Reagents
Anti-MCP-1 polyclonal Ab (anti-rat MCP-1 goat IgG) and control (nonimmunized) goat IgG were generously provided by Toray Basic Research Laboratory (Kanagawa, Japan). The neutralizing activity of this purified polyclonal anti-rat MCP-1 Ab was confirmed by monocyte chemotaxis assay. 18 This Ab shows no cross-reactivity against recombinant rat RANTES and detected a single band in the same fraction as recombinant rat MCP-1 on Western blot analysis, when concanavalin A-stimulated spleen cell culture supernatant was fractionated by heparin-HPLC. 18 Recombinant rat MCP-1 that contained Ͻ0.1 ng endotoxin/mg of rat MCP-1 protein (data from the manufacturer) was obtained from DIACLONE Research. Recombinant human platelet-derived growth factor (PDGF) was purchased from Gibco/BRL.
Animal Model Preparation
Male Sprague-Dawley rats 11 to 12 weeks old were obtained from Shizuoka Agricultural Cooperation Association. The animals were housed in plastic and stainless-steel cages, with controlled 12-hour light/12-hour dark cycles and access to food and water as desired. They were anesthetized with sodium pentobarbital (50 mg/kg IP). The endothelium of the left common carotid artery was denuded by 3 passages of an inflated 2F Fogarty embolectomy catheter (Baxter Health Care) with a modification of the method of Clowes et al. 19 
RNA Preparation and cDNA Synthesis
Carotid arteries were harvested at 1, 2, 4, 8, 24, 72, or 120 hours after balloon injury (nϭ3 for each time period). Noninjured left common carotid arteries of Sprague-Dawley rats were used as normal controls (nϭ3). Total RNA was prepared from the arteries by the guanidinium thiocyanate/phenol/chloroform/isoamylalcohol isolation method. 20 One microgram of total RNA template was subjected to first-strand cDNA synthesis with dNTP (Perkin-Elmer Corp) and Moloney murine leukemia virus reverse transcriptase (Gibco/BRL) under supplier-recommended conditions.
Competitive PCR
To estimate MCP-1 mRNA expression quantitatively, competitive PCR analysis was performed as previously described. 21 Genespecific oligonucleotide primers and mimic PCR primers for the MCP-1 and GAPDH genes were purchased from Oligos Etc, Inc. A sense primer (A) and an antisense primer (B) for each were synthesized using the published cDNA sequences for MCP-1 22 and GAPDH 23 as follows.
Gene-Specific Primers
MCP-1 (A): 5Ј-CGGAATTCCGAACTCTCACTGAAGCCAGAT- CTCT-3Ј MCP-1 (B): 5Ј-CCAAGCTTGGAGGTGAGTGGGGCATTAA- CTGCAT-3Ј GAPDH (A): 5Ј-TGAAGGTCGGTGTGAACGGATTTGGC-3Ј GAPDH (B): 5Ј-CATGTAGGCCATGAGGTCCACCAC-3Ј
Mimic PCR Primers
Mimic MCP-1 (A): 5Ј-AACTCTCACTGAAGCCAGATCTCTCG-CAAGTGAAATCTCCTCCG-3Ј Mimic MCP-1 (B): 5Ј-AGGTGAGTGGGGCATTAACTGCATGG-GACAAGATACTCATCTGC-3Ј Mimic GAPDH (A): 5Ј-TGAAGGTCGGTGTGAACGGATTTGG-CCGCAAGTGAAATCTCCTCCG-3Ј Mimic GAPDH (B): 5Ј-CATGTAGGCCATGAGGTCCACCACT-TGAGTCCATGGGGAGCTTT-3Ј PCR-mimic cDNA (internal control) was created according to the manufacturer's instructions (PCR MIMIC construction kit, Clontech). Twofold dilutions of each PCR mimic between 10 Ϫ2 and 10
Ϫ5
were added to the PCR amplification reaction mixture containing 1 L of sample cDNA and an aliquot of [␣ 32 P]dCTP for each reaction. Both MCP-1 and GAPDH cDNA were analyzed by 30 cycles of amplification in a thermal cycler (Perkin-Elmer Corp). Each cycle consisted of denaturation at 94°C for 45 seconds, annealing at 50°C for 45 seconds, and extension at 72°C for 90 seconds. A portion of each PCR product was electrophoresed on a 4% polyacrylamide gel, and the densitometric values of 32 P-labeled target and internal control were analyzed with a FUJIX bioimaging analyzer (BAS 2000) . The molar ratio between target and internal control was calculated with the following formula: target/internal controlϭ(V T /V C )ϫ(C C /C T ), where V T and V C represent the densitometric value of the PCR product from target and internal control, respectively, and C C and C T represent the dCTP content in the PCR product from internal control and target. The amount of target gene was determined as that of the internal control at the point of an equal molar ratio between the target and the internal control ( Figure 1A) . The relative amount of MCP-1 cDNA was corrected by the amount of GAPDH cDNA. The calculated values were finally normalized for each by assigning a standard number of 1 to the sample that demonstrated the highest normalized MCP-1 expression.
Enzyme-Linked Immunosorbent Assay
Carotid arteries were harvested at 2, 8, 24, or 120 hours after injury (nϭ3 for each time period). Right common carotid arteries were used as controls. The total length of each common carotid artery was homogenized in 1 mL of PBS containing 0.05% NaN 3 with an ultrasonic processor, ASTRASON (Misonix Inc), and then centrifuged. MCP-1 in the supernatant was quantified using an ELISA kit (Biosource International). All measurements were performed in duplicate. The values were corrected by protein concentrations measured by a modification of Lowry's method. 24 
Experiment 1
Animals were randomly assigned to an anti-MCP-1 treatment group or to a control group. Rats in the anti-MCP-1 treatment group (nϭ5) received 10 mg/kg anti-MCP-1 Ab, via the tail vein, 30 minutes before arterial injury and 12 and 24 hours after the first injection. Control rats (nϭ5) were given 10 mg/kg nonimmunized goat IgG.
Experiment 2
Rats in the anti-MCP-1 treatment group (nϭ6) and control group (nϭ6) received 10 mg/kg anti-MCP-1 Ab or nonimmunized goat IgG, respectively, via the tail vein, every 12 hours for 5 days starting at 30 minutes before injury. This second series of experiments was performed to test the value of a longer treatment with anti-MCP-1 Ab.
Experiment 3
To determine the persistence of the inhibitory effects of anti-MCP-1 Ab on neointimal hyperplasia, the arteries were examined 56 days after carotid arterial injury, when cell proliferation in the injured arterial walls returns to the basal level. 19 Rats in the anti-MCP-1 treatment group (nϭ5) and the control group (nϭ5) received 5 doses of 10 mg/kg anti-MCP-1 Ab or nonimmunized goat IgG, respectively, via the tail vein, every 12 hours starting at 30 minutes before injury. This third series of experiments was performed to test whether the inhibitory effect was limited to a delay of lesion progression.
Light-Microscopic Examination and Morphometry of Neointima
Fourteen days after injury in experiments 1 and 2, and 56 days after injury in experiment 3, the rats were anesthetized with sodium pentobarbital (50 mg/kg, IP) and received 200 L of 2% Evans blue dye in PBS injected into the tail vein. They then received heparin (100 U/rat) intravenously, and after perfusion with saline, the left common carotid arteries were perfusion fixed with 10% neutral buffered formalin as described previously. 25 The carotid arteries were removed and fixed further. Central portions of the blue-stained areas were embedded in paraffin. Five cross sections of each artery situated 2 mm and 1 mm proximal to the center, at the center, and 1 mm and 2 mm distal to the center, were stained with elastic van Gieson stain. Intimal and medial areas were blindly measured with a computer-based image analyzing system (LUZEX3U, Nikon). The mean intimal and medial areas of each artery were determined from these 5 sections.
Immunohistochemical Staining
Immunohistochemical staining was performed to evaluate the effects of anti-MCP-1 Ab on (1) accumulation of macrophages in the neointima, (2) the number of VSMCs in the early neointimal lesion, and (3) initial medial proliferation of VSMCs. For these 3 experiments, rats in the anti-MCP-1 treatment group and in the control group received 3 doses of 10 mg/kg anti-MCP-1 Ab and nonimmunized goat IgG, respectively, as described in experiment 1. For the staining of macrophages, the carotid arteries were removed 14 days after injury and embedded in OCT compound tissue medium (Miles Inc). Short axial 4-m cryostat sections were cut from proximal, middle, and distal segments for each sample and fixed for 10 minutes in acetone at 4°C. To label macrophages, ED1 Ab (BMA Biomedicals Ltd) 26 was used as primary Ab. Labeling of VSMCs or proliferating cells was performed using the 20 or the 5 formalinfixed, deparaffinated sections of carotid arteries obtained at day 4 or 48 hours, respectively. As primary Ab, mouse monoclonal Ab against muscle actin (HHF35, ENZO Diagnostics Inc) or mouse monoclonal Ab against proliferating cell nuclear antigen (PCNA; PC10, YLEM Srl) was used. The sections were incubated with the following: primary Ab at a dilution of 1:50 overnight at 4°C, biotinylated secondary Ab (rabbit anti-mouse IgG; DAKO) at 1:500 for 30 minutes at room temperature, and Vector Elite ABC biotinavidin-peroxidase complex for 30 minutes. The sections were developed with 3,3Ј-diaminobenzidine (Dojindo) solution and counterstained with hematoxylin. For negative controls, normal mouse IgG or normal rabbit IgG was used instead of primary or secondary Ab. Cell number was counted for each sample at a magnification of ϫ400.
Cell Culture
Rat aortic VSMCs for migration assay were prepared by the explant method. 27 VSMCs migrated from dissected rat aorta were grown in DMEM (Nissui) supplemented with 10% FCS, 100 g streptomycin/ mL, and 100 units penicillin/mL (Gibco/BRL) in a humidified atmosphere (5% CO 2 /95% air) at 37°C. Cells from the third through the seventh passages were used in each assay.
VSMC Migration Assay
Migration of rat aortic VSMCs was assayed with a 48-well modified Boyden-chamber apparatus (Neuro Probe Inc). 28, 29 The wells were covered with a polyvinylpyrrolidone-free filter with 8-m pores (Nuclepore Corp), coated with 2.7 g/well Matrigel (Collaborative Research), 29 or 100 g/mL type I collagen (Sigma). Cultured VSMCs were trypsinized and suspended at a concentration of 5.0ϫ10 5 cells/mL in serum-free DMEM with streptomycin and penicillin. Fifty microliters of the cell suspension was added to each upper chamber. DMEM containing recombinant rat MCP-1 at the final concentration of 20, 50, or 100 ng/mL was added to the lower chamber in a volume of 50 L. As negative and positive controls, DMEM without MCP-1 and DMEM with recombinant human PDGF-BB (Gibco/BRL), with a final concentration of 20 ng/mL were used, respectively. To test whether MCP-1 can augment the chemotactic activity of VSMCs when PDGF-BB was used as a chemoattractant, MCP-1 was added to the upper chamber at a final concentration of 50 ng/mL in some of the experiments. Six filters were used for each treatment. After incubation in a humidified atmosphere (5% CO 2 /95% air) at 37°C for 12 hours, the cells on the upper membrane surface were removed, and those on the lower surface were fixed in methanol and stained with Diff-Quik staining solution (International Reagents Corp). The number of cells per four 200ϫ high-power fields was counted under a microscope, and the mean number of cells represented migration activity.
Statistical Analysis
Values for relative MCP-1 gene-product levels and MCP-1 immunoreactivity are expressed as meanϮSEM. Values for intimal areas, medial areas, intima/media ratio, numbers of cells, percentage ED1-positive cells, percentage proliferating cells, and migration activity are expressed as meanϮSD. Values for intimal areas and intima/media ratio in experiment 3 were compared using the MannWhitney U test, since they were nonparametrically distributed. Values for migration activity were compared using ANOVA. Other values were compared using the 2-tailed unpaired Student t test.
Results
Time Course of MCP-1 Gene Expression in Injured Rat Carotid Arteries
Coamplification of sample cDNA with serially diluted mimic cDNA showed a close correlation between the amount of mimic cDNA and target cDNA/mimic cDNA ratio for each reaction ( Figure 1A) . Induction of MCP-1 mRNA was demonstrable as early as 1 hour, and peak expression occurred at 4 hours after arterial injury ( Figure 1B ). MCP-1 mRNA level decreased at 8 hours, although relatively low but upregulated MCP-1 gene expression was still present 120 hours after injury.
Enhanced MCP-1 Immunoreactivity in the Injured Arterial Wall
Immunoreactivity of MCP-1 in the injured arteries increased as early as 2 hours after injury (129.0Ϯ6.8 pg/mg protein; meanϮSEM), and the upregulation was still detectable at 8 (118.5Ϯ18.3) and 24 hours (82.5Ϯ14.6). At 120 hours, MCP-1 immunoreactivity had returned to the level of noninjured arteries. In the noninjured arterial tissues, no significant changes were observed throughout the observation period ( Figure 2 ).
Effects of Anti-MCP-1 Treatment on Neointimal Hyperplasia
Significant neointimal hyperplasia was observed in injured arteries 14 days after injury. Intravenous administration of 3 doses of anti-MCP-1 Ab significantly inhibited neointimal hyperplasia, compared with the control group (Table 1, Figure 3A ). The mean intima/media ratio was reduced to 0.679Ϯ0.174 (meanϮSD), in contrast to 0.941Ϯ0.062 in the control group (PϽ0.05), representing a 27.8% inhibition in the anti-MCP-1 treatment group. Administration of anti-MCP-1 Ab every 12 hours for 5 days (10 doses) resulted in 43.6% inhibition (Table 1 , Figures 3B and 4) . The mean intima/media ratio was 0.465Ϯ0.163 in the anti-MCP-1-treated group versus 0.825Ϯ0.093 in the control group (PϽ0.01). In experiment 3, this inhibitory effect was still present 56 days after injury, and the mean intima/media ratio was reduced by 55.6% in the anti-MCP-1 treatment group (PϽ0.05; Table 1 , Figures 3C and 4) .
Population of Macrophages in the Neointima
The number of nuclei and ED1-positive cells in the neointima of 3 sections was counted for each sample, and the percentage of ED1-positive cells was calculated. The number of ED1-positive cells in the neointima tended to be lower in the anti-MCP-1 treatment group (80Ϯ26 in the anti-MCP-1 treatment group versus 115Ϯ27 in the control group; Pϭ0.054). The number of nucleated cells also tended to be lower (1646Ϯ273 in the anti-MCP-1 treatment group versus 2074Ϯ419 in the control group; Pϭ0.071). As a result, the percentages of ED1-positive cells relative to the nucleated cells in the neointima were comparable in both groups (4.81Ϯ1.03% in the anti-MCP-1 treatment group versus 5.50Ϯ0.65% in the control group; Pϭ0.228, Table 2 ).
Effect of Anti-MCP-1 Ab on the Number of VSMCs in Early Neointimal Lesions
In this rat model, VSMCs appear in the intima 4 days after injury. 19 The number of intimal VSMCs was thus compared between the anti-MCP-1 treatment group and the control group at day 4, representing migration activity and intimal proliferation of VSMCs in the early neointimal lesion. Table  3 shows that the number of VSMCs in the intima was decreased by treatment with anti-MCP-1 Ab (PϽ0.05).
Effect of Anti-MCP-1 Ab on Initial Medial Proliferation After Mechanical Injury
Forty-eight hours after injury, immunohistochemical staining with anti-PCNA Ab showed no differences, between the anti-MCP-1 treatment group and the control group, in the population of proliferating cells in the media (Table 4) . Percentage PCNA-positive cells was 35.8Ϯ2.9% in the anti-MCP-1 treatment group, and that in the control group was 34.4Ϯ7.2%.
Effects of MCP-1 on VSMC Migration In Vitro
Recombinant rat MCP-1 failed to stimulate chemotactic activity of VSMCs into coated Matrigel, even at high concentrations, which have been observed to exert a significant effect in a monocyte chemotaxis assay. 18 MCP-1 also failed to increase PDGF-BB-stimulated VSMC migration activity when added directly into the upper chamber ( Figure 5 ). Similar results were obtained in the assays using type I collagen as a coating material (data not shown).
Discussion
The present study shows that anti-MCP-1 treatment before and soon after arterial injury reduced neointimal hyperplasia, an effect that persisted during the chronic stage. Rats that had undergone carotid arterial injury were treated with anti-MCP-1 Ab for different lengths of time. Treatment for 5 days (10 doses) seemed more effective in limiting the neointimal lesions than treatment limited to 3 doses, although there was not a notable difference in the inhibitory effects between the 2 treatment durations. This suggests that anti-MCP-1 treatment exerts beneficial effects mostly by neutralizing MCP-1 produced soon after arterial injury. We demonstrated in experiment 3 that the effects of early anti-MCP-1 treatment did not just delay the development of neointimal lesions, but also influenced the severity of neointimal hyperplasia in the chronic stage. As a possible mechanism of the inhibitory effect of anti-MCP-1 treatment, it is noteworthy that the number of VSMCs in the early neointimal lesions at day 4 decreased significantly. In addition, the accumulation of macrophages tended to decrease with anti-MCP-1 treatment. These observations suggest an important role of MCP-1 in the development of accelerated atherosclerosis. In the pathogenesis of atherosclerosis, various vascular and inflammatory cells, including monocytes/macrophages and VSMCs, play important interacting roles. 6, 7, 19 Soluble factors and adhesion molecules regulate the pathophysiological activities of these cells. 30 -35 As MCP-1 is one of the soluble factors that participate in atherogenesis, the pathophysiological roles of MCP-1 have been studied in cultured cells. Expression of MCP-1 is regulated by various stimuli such as growth factors 36, 37 and those from adhesion molecules. 30 In this study, MCP-1 mRNA and protein were rapidly induced by mechanical arterial injury, with a time course comparable to that in previous experiments performed in a rabbit model. 8 Because MCP-1 is a potent chemoattractant of monocytes, 9,10 this induction of MCP-1 may contribute to early inflammatory responses in the injured arterial walls and local accumulation of monocytes/macrophages into the neointima. Recently, Boring et al 38 reported that additional depletion of CCR2 gene, a receptor for MCP-1, to apolipoprotein E (ApoE) gene markedly attenuated atherosclerotic lesions in ApoE-deficient mice by inhibiting macrophage accumulation; these results strongly support the important role of MCP-1 in atherosclerotic lesion formation, particularly macrophage-rich lesions. In fact, in our experiments, the number of macrophages accumulated in the neointima tended to be decreased by anti-MCP-1 Ab treatment, although the population of macrophages is smaller in the rat than in other models of arteriosclerosis. 39, 40 This may partially explain the inhibitory effects of anti-MCP-1 Ab on neointimal hyperplasia in the rat arterial injury model.
In addition to its well-known chemotactic activity on monocytes/macrophages, other properties of MCP-1 have Figure 4 . Photomicrographs of representative cross sections of rat common carotid arteries. A, Section of the injured left common carotid artery from a rat treated with nonimmunized goat IgG in experiment 2. Significant diffuse neointimal hyperplasia is present in the injured arterial wall. B, Section of the injured left common carotid artery from a rat treated with anti-MCP-1 Ab in experiment 2. Neointimal hyperplasia is less prominent. C, Section of a noninjured right common carotid artery from a rat treated with nonimmunized goat IgG in experiment 2. D, Section of an injured left common carotid artery from a rat treated with nonimmunized goat IgG, euthanized 56 days after injury in experiment 3. Neointimal hyperplasia has progressed in comparison with rats euthanized at day 14 in experiment 2. E, Section of an injured left common carotid artery from a rat treated with anti-MCP-1 Ab in experiment 3. The inhibitory effect of anti-MCP-1 treatment persisted 56 days after injury. Barϭ100 m; elastic van Gieson stain. been described that may stimulate atherosclerotic-lesion formation. Some investigators have reported that MCP-1 stimulates chemotaxis of T lymphocytes 41, 42 and VSMCs. 43, 44 Ikeda et al 45 reported that MCP-1 increased the expression of intercellular adhesion molecule-1 on rat aortic VSMCs. Another study has shown that MCP-1 has direct mitogenic effects on the proliferative response of cultured rat VSMCs, 17 although controversy remains. 16 Thus, several reports have shown biological effects of MCP-1 on VSMCs, despite the absence of a clear demonstration of receptors for MCP-1. Recent observations suggest the existence of chemokine receptors for MCP-1 on the surface of VSMCs. Schecter et al 46 reported that human VSMCs may express a distinct receptor for MCP-1 from CCR2, which is expressed on monocytes and T lymphocytes, by binding assay and reverse transcriptase-PCR, and another group demonstrated the expression of CCR2 mRNA in unstimulated cultured human VSMCs. 47 There is a discrepancy between these 2 reports with respect to the type of VSMC receptor. Nevertheless, they suggest that MCP-1 may modulate the function of VSMCs and that neutralization of MCP-1 may inhibit neointimal lesion formation not only by reducing the accumulation of monocytes/macrophages, but also by blocking the biological effects of MCP-1 on VSMCs. Since the intimal population of macrophages is much greater in humans than in this rat model, the clinical effects of anti-MCP-1 treatment cannot be immediately predicted. However, together with the reduction of macrophage-rich atherosclerotic lesions by CCR2 gene depletion in a recent study, 38 the inhibitory effects of anti-MCP-1 treatment in this rat model suggest that such treatment may reduce the formation of neointimal lesions after balloon angioplasty, lesions that contain more VSMCs and fewer macrophages than primary atherosclerotic plaques. 48 Previous studies have suggested that migration and intimal proliferation are more critical steps in the development of intimal hyperplasia than first-round medial VSMC proliferation in this model. Neutralization of basic fibroblast growth factor with anti-basic fibroblast growth factor Ab markedly inhibited initial medial VSMC proliferation but not the associated intimal lesion, 31 whereas anti-PDGF treatment inhibited neointimal hyperplasia at day 8 after injury, with no difference observed in the proportion of proliferating VSMCs found in the media and intima between anti-PDGF-treatment and control groups. 3 To investigate the role of MCP-1 in early neointimal lesion formation, we tested the effects of anti-MCP-1 Ab on the number of VSMCs in the neointima on day 4, which reflects the migration of medial VSMCs into the neointima and the early intimal proliferation of migrated VSMCs. We also examined the effects of anti-MCP-1 Ab on the number of proliferating medial VSMCs at 48 hours, which reflects first-round proliferative response in the media. The results showed a significant difference in the number of intimal VSMCs on day 4 between anti-MCP-1 treatment group and control group, but no difference in the number of proliferating VSMCs at 48 hour, suggesting that MCP-1 stimulates migration or intimal proliferation of VSMCs in vivo. The effects of recombinant MCP-1 on migration of cultured VSMCs were then examined. In the migration assay, MCP-1 did not directly act as a chemoattractant for VSMCs, nor did it stimulate migration activity of VSMCs into Matrigel or collagen I. Our results differ from those of previous reports with regard to the effects of MCP-1 on VSMC migration. 43, 44 Differences in the species of experimental cells used, or in the preparation of the cells, may explain this discrepancy. It is also possible that the effects of MCP-1 on VSMC migration in vivo are different from those in a cell culture. Nevertheless, the results of the migration assay suggest other effects of MCP-1 on VSMCs causing an early decrease in the number of VSMCs in the intima. Since there was no difference in the number of proliferating medial VSMCs between the anti-MCP-1 treatment group and the control group, we considered the possibility that anti-MCP-1 treatment did not affect first-round medial VSMC proliferation. However, the possibility that anti-MCP-1 Ab inhibited second-round proliferation of VSMCs in the intima cannot be excluded, since the proliferative activity of VSMCs in the injured arterial walls is biphasic, 49 and Ͼ70% of intimal VSMCs are proliferating at day 4. 19 Thus, a decrease in the number of VSMCs in the neointima by anti-MCP-1 treatment at day 4 could result from inhibition of second-wave VSMC proliferation in the intima. Studies using cultured VSMCs revealed variable proliferative responses of VSMCs to MCP-1 depending on the status of the cells. 16, 17 It is, therefore, possible that differences exist in between the proliferative responses of intimal VSMCs versus medial VSMCs. Another possible biological effect of MCP-1 on VSMCs, which may enhance the second wave of proliferative response, consists of stimulation and prolongation of procoagulant activity. MCP-1 produced by VSMCs and macrophages may induce procoagulant activity and contribute to mural thrombus formation via tissue-factor induction in atherosclerotic lesions. 46 Thrombi that are formed after arterial injury contain chemoattractants and mitogens for VSMCs and seem to function as a matrix for the migration and proliferation of VSMCs. 50 Therefore, anti-MCP-1 treatment may attenuate neointimal hyperplasia by reducing procoagulant activity in the injured arterial walls.
TABLE 2. Populations of ED1-Positive Cells in the Neointima
In conclusion, this study demonstrated that the expression of MCP-1 was induced early in a rat model of carotid arterial injury. Anti-MCP-1 treatment resulted in a significant attenuation of neointimal hyperplasia in studies of 2 different treatment periods, and the inhibitory effect persisted long after injury. As a possible mechanism of this inhibitory effect, neutralization of MCP-1 may affect not only accumulation of macrophages but also an early increase of VSMCs in the intima. These results suggest that MCP-1 acts as an early promoting factor in neointimal hyperplasia after mechanical injury and that anti-MCP-1 treatment before and soon after angioplasty may inhibit postprocedural intimal hyperplasia. Further investigations are needed to clarify the diverse biological effects of MCP-1 on both leukocytes and vascular cells in neointimal lesion formation and to measure the efficacy of anti-MCP-1 treatment in the prevention of restenosis after balloon angioplasty.
